FOXA1 and prostate carcinoma: Interestingly, the frequency of FOXA1 mutations in primary prostate tumors is much higher in a Chinese cohort of prostate cancer patients compared to the largely European-centric cohort of the TCGA, with a frequency of ~41% in the former cohort compared to 4% in the latter (35), suggesting ethnic variation with regards to FOXA1 mutations among prostate cancer patients.